D-0166-2027 Class II Ongoing

Recalled by Hikma Pharmaceuticals USA INC. — Columbus, OH

FDA drug recall D-0166-2027 was initiated by Hikma Pharmaceuticals USA INC. on Oct 20, 2026 and is designated Class II. Reason for recall: CGMP Deviations: N-nitroso-ciprofloxacin results above the FDA recommended interim control limit. The recall status is ongoing. Affected quantity: 20,335 bottles.

Recall details

Product Type
Drugs
Report Date
Nov 11, 2026
Initiation Date
Oct 20, 2026
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
20,335 bottles

Product description

Ciprofloxacin Tablets, USP, 750 mg, 50-count bottle, Rx Only, Manufactured by: Hikma Pharmaceuticals, P.O. Box 182400, Amman, 11118-Jordan, Distributed by: Hikma Pharmaceuticals USA Inc. Berkely Heights, NJ 07922, NDC 0143-9929-50

Reason for recall

CGMP Deviations: N-nitroso-ciprofloxacin results above the FDA recommended interim control limit.

Distribution pattern

US Nationwide

Code information

Lot# CA083A Exp. 12/31/2026 Lot# CA084A Exp. 12/31/2026 Lot# CA085A Exp. 12/31/2026

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0166-2027
openFDA file date
Nov 19, 2026
Loaded by RegDataLab
Nov 20, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Need the full FDA record for Hikma Pharmaceuticals USA INC.? Ask Claude or ChatGPT with the RegDataLab connector and get every site's inspections, Form 483s, warning letters, recalls and import alerts, each with a link to the FDA source. The API key is free: no card.

Get a free API key

How the connector works

Source: openFDA record for D-0166-2027. Report a data issue: hello@regdatalab.com.